BC Innovations | May 23, 2019
Emerging Company Profile

Obsidian: Fine-tuning therapeutic protein expression with approved drugs

Obsidian is building a tool kit of engineered proteins whose expression can be finely tuned with FDA-approved small molecules, and its first application is in boosting the efficacy of cell therapies through a deal with...
BC Week In Review | Jun 9, 2017
Clinical News

Ziopharm reports Phase I OS data for Ad-RTS-hIL-12 in GBM

Ziopharm Oncology Inc. (NASDAQ:ZIOP) reported data from 15 evaluable patients with recurrent or progressive glioblastoma multiforme (GBM) or grade III/IV malignant glioma in a Phase I trial showing that a single intratumoral injection of Ad-RTS-hIL-12...
BC Innovations | May 18, 2017
Product R&D

Making cells compute

With efficiency in DNA engineering continuing to grow, and an increasing convergence between engineering and biology, synthetic biology -- in its “truest” form -- is coming within striking distance of translating preclinical proof of concept...
BC Extra | May 12, 2017
Financial News

Ziopharm raises $50M in follow-on

Cancer company Ziopharm Oncology Inc. (NASDAQ:ZIOP) raised $50 million through the sale of 9.7 million shares at $5.15 in a follow-on underwritten by Guggenheim. The price is a 28% discount to Ziopharm's close of $7.12...
BC Week In Review | Dec 1, 2016
Clinical News

Ad-RTS-hIL-12: Preliminary Ph Ib/II data

Preliminary data from 9 evaluable patients with locally advanced or metastatic breast cancer in an open-label, U.S. Phase Ib/II trial showed that 1x10 12 viral particles per injection of intratumoral Ad-RTS-hIL-12 plus the oral activator...
BC Week In Review | Jul 25, 2016
Clinical News

Ad-RTS-hIL-12: Phase I ongoing

Ziopharm reported 3 patient deaths that were unrelated to treatment in an open-label, U.S. Phase I trial evaluating a single intratumoral injection of Ad-RTS-hIL-12 plus escalating doses of daily oral veledimex for 14 days. The...
BC Extra | Jul 19, 2016
Company News

Ziopharm says patient death was unrelated to treatment

Ziopharm Oncology Inc. (NASDAQ:ZIOP) said a patient death disclosed on Friday was not related to treatment with gene therapy candidate Ad-RTS-hIL-12 . The death, due to intracranial hemorrhage, was one of three Ziopharm had said occurred...
BC Extra | Jul 15, 2016
Clinical News

Ziopharm slides on news of patient deaths

Ziopharm Oncology Inc. (NASDAQ:ZIOP) lost $0.66 (12%) to $5.01 on Friday after it reported three patient deaths in a Phase I study of Ad-RTS-hIL-12 to treat recurrent or progressive glioblastoma multiforme (GBM) or grade III...
BC Innovations | Feb 4, 2016
Tools & Techniques

Calibrating CARs

Instead of focusing on how to turn chimeric antigen receptor (CAR) T cells off when things go wrong, a group at the California Institute for Biomedical Research (Calibr) has engineered a universal CAR T cell...
BC Week In Review | May 11, 2015
Clinical News

Ad-IL-12: Phase I started

Ziopharm began an open-label Phase I trial to evaluate a single intratumoral injection of Ad-IL-12 in combination with 20, 30, 80 or 120 mg oral veledimex, an activator ligand, once daily for 14 days in...
Items per page:
1 - 10 of 18